Grant: Master's Award: Canada Graduate Scholarships
University of British Columbia
$17,500.00
Discovery of direct- and indirect-acting antivirals against Zika virus
FY 2016-17
Summary
The spread of viral infection on a global scale has been made possible by the ease of worldwide travel. In April 2016 the World Health Organization declared the Zika virus (ZIKV) to be a public health emergency of international concern. The ZIKV has since spread to 26 countries and has been determined to cause neuronal disorders such as Guillain-Barre and microcephaly. Although the ZIKV was first discovered 70 years ago, there is still no available effective treatment or vaccine. Therefore, to address the urgent need for therapeutic agents I will be screening potential compounds for anti-ZIKV activity. These potential anti-ZIKV compounds include pre-existing FDA approved drugs, purified natural products and marine/microbial extracts. To find candidates that combat ZIKV infection the initial stage is to test for cell toxicity in neural stem cells. By testing for cell toxicity only potential compounds that do not produce adverse side effects have the potential to be used as future drugs. All compounds that make it through the initial toxicity screen will then be tested for anti-ZIKV activity by measuring the amount of ZIKV proteins produced in infected cells in the presence and absence of each compound. This is done using a pre-existing assay in the Jean Lab. Compounds that are shown to lower the severity of or prevent ZIKV infection will further be tested using pre-existing screening techniques to determine if they inhibit the ZIKV directly or prevent viral infection through modifying the cell itself. Overall, this study could identify new anti-ZIKV drugs. It is hoped that the results of this study bring a form of relief to many of the people infected with ZIKV currently and in the future as the outbreak continues.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
British Columbia, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
367231
Name
Long Rory K
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Discovery of direct- and indirect-acting antivirals against Zika virus
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Anti-Viral Therapy; Broad-Range Antivirals; Cell Biology; Direct-Acting Antivirals; Indirect-Acting Antivirals; Mass Spectometry; Neural Stem Cells; Screening Assays; Virology; Zika Virus
Abstract
The spread of viral infection on a global scale has been made possible by the ease of worldwide travel. In April 2016 the World Health Organization declared the Zika virus (ZIKV) to be a public health emergency of international concern. The ZIKV has since spread to 26 countries and has been determined to cause neuronal disorders such as Guillain-Barre and microcephaly. Although the ZIKV was first discovered 70 years ago, there is still no available effective treatment or vaccine. Therefore, to address the urgent need for therapeutic agents I will be screening potential compounds for anti-ZIKV activity. These potential anti-ZIKV compounds include pre-existing FDA approved drugs, purified natural products and marine/microbial extracts. To find candidates that combat ZIKV infection the initial stage is to test for cell toxicity in neural stem cells. By testing for cell toxicity only potential compounds that do not produce adverse side effects have the potential to be used as future drugs. All compounds that make it through the initial toxicity screen will then be tested for anti-ZIKV activity by measuring the amount of ZIKV proteins produced in infected cells in the presence and absence of each compound. This is done using a pre-existing assay in the Jean Lab. Compounds that are shown to lower the severity of or prevent ZIKV infection will further be tested using pre-existing screening techniques to determine if they inhibit the ZIKV directly or prevent viral infection through modifying the cell itself. Overall, this study could identify new anti-ZIKV drugs. It is hoped that the results of this study bring a form of relief to many of the people infected with ZIKV currently and in the future as the outbreak continues.
Competitiondate
201612
Approvedterm2
1 yr 0 mth
Pinamesdelim
Long, Rory K
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~